AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|
22.6 C
New York
Wednesday, September 2, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1releasesmarket

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons

BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

United Breast Cancer Foundation Expands Support in the Southeast with Major Mattress & Pink Bag Event in Tallahassee, FL

130 Breast Cancer Patients and Survivors Served During Five-Day Distribution of Donated Essentials TALLAHASSEE, Fla., July 22, 2025 /PRNewswire/ -- United Breast Cancer Foundation (UBCF)...

QuidelOrtho to Report Second Quarter 2025 Financial Results

SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed...

Sparkling Ice and Giant Eagle join forces to support military veterans struggling with invisible wounds of war

Sparkling Ice and Giant Eagle have teamed up to sponsor a PTSD service dog through K9s For Warriors, whose mission is to end veteran suicide.

Manali A. Shendrikar, MD, MPH Is the Latest Physician from Saint John’s Physician Partners to Offer the Hybrid Choice™ Concierge Program from Concierge Choice...

Leading not-for-profit healthcare organization in greater Los Angeles allows patients to choose a closer doctor-patient relationship ROCKVILLE CENTRE, N.Y., July 22, 2025 /PRNewswire/ -- Concierge Choice Physicians (CCP),...

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Ignored and Undiagnosed: Sleep Apnea Threatens Women’s Cognitive Health

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...

Japan In Vitro Diagnostics Market Report and Forecast 2025-2034

The Japan in vitro diagnostics market, valued at USD 3.97 Billion in 2024, is projected to grow at a CAGR of 6.20%, reaching USD 7.24 Billion by 2034. Key growth drivers include an aging population, demand for personalized medicine, AI-integrated testing, and home-based diagnostics. Strategic partnerships and regulatory approvals boost market potential. 
The Japan in vitro diagnostics market, valued at USD 3.97 Billion in 2024, is projected to grow at a CAGR of 6.20%, reaching USD 7.24 Billion by 2034. Key growth drivers include an aging population, demand for personalized medicine, AI-integrated testing, and home-based diagnostics. Strategic partnerships and regulatory approvals boost market potential.

Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas, July 22, 2025 /PRNewswire/ -- Caris Life...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers